January 18, 2017

Biotechnology, Life Sciences, Food and Drug Law News

The National Law Review features a wide variety of content on issues important to life sciences companies, including biosimilars, biotechnology, medical devices, drug pricing, nanotechnology, and pharmaceuticals.  Our content reviews the impact the latest legal changes have on these industries, such as the 21st Century Cures Act. With all of these areas, our content covers issues such as licensing and patents, intellectual property, due diligence, litigation and tax implications.

We also have legal expertise on marketing compliance, licensing and collaborations, and bringing new products to market.  Additionally, the National Law Review is a source for all the latest legal news and regulatory compliance issues involving food and cosmetics safety and labeling requirements, activities of the Food and Drug Administration (“FDA”) and the US Department of Agriculture (“USDA”).

Date Title Organization
18
Jan
FDA Issues Discussion Paper on Possible Regulatory Approach for Laboratory Developed Tests Covington & Burling LLP
18
Jan
FDA Issues Final Guidance on Benefit-Risk for Investigational Device Exemptions Barnes & Thornburg LLP
18
Jan
The Trump Administration’s View on Marijuana: Reading the (Tea) Leaves McDermott Will & Emery
18
Jan
FDA to Hold Public Hearing on Partnerships to Enhance Safety of Imported Foods Keller and Heckman LLP
18
Jan
340B Update: HRSA Finalizes 340B Pricing & Penalties for Drug Manufacturers K&L Gates
17
Jan
Federal Circuit’s Eli Lilly Decision Clarifies the Direction or Control Standard in Dividend Infringement Michael Best & Friedrich LLP
17
Jan
Massachusetts Has Legalized Marijuana — Should Your Workplace Policies Go Up in Smoke? Foley & Lardner LLP
17
Jan
Supplement Spotlight: FDA Revised NDI Draft Guidance Does Not Alleviate Industry’s Concerns Keller and Heckman LLP
17
Jan
FDA’s Enforcement Priorities Likely to Change in 2017 and Other “Unknowable Knowns” Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
17
Jan
TTB Publishes Federal Register Notice Adjusting Civil Monetary Penalty under ABLA McDermott Will & Emery
17
Jan
Medical Marijuana Comes to Pennsylvania: What to Expect As the Keystone State Rolls Out its New Medical Marijuana Program K&L Gates
17
Jan
What Is The Trump Pharmaceutical Policy? Foley & Lardner LLP
16
Jan
Regulating Commercial Food Activites: Be Fair, or the (Polish) Government Will Chase You! Squire Patton Boggs (US) LLP
16
Jan
Two Important Decisions Addressing ANVISA’s Prior Approval of Pharmaceutical Patents in Brazil Michael Best & Friedrich LLP
16
Jan
Supreme Court Will Judge Biosimilar Patent Dance Foley & Lardner LLP
14
Jan
EPA Proposes Ban of TCE for Use in Vapor Degreasing Bergeson & Campbell, P.C.
13
Jan
Eighth Circuit Rules That ERISA Expressly Preempts Iowa Pharmacy Benefit Law McDermott Will & Emery
13
Jan
Boozelaw: TTB Adopts Changes Designed to Benefit Startup Brewers, Winemakers and Distillers Varnum LLP
13
Jan
FDA Issues Revised Draft Guidance for Control of Listeria monocytogenes in Ready-To-Eat Foods Keller and Heckman LLP
12
Jan
Ninth Circuit Rejects Administrative Infeasibility As A Basis For Decertifying Class Actions Keller and Heckman LLP

Pages

LATEST LEGAL NEWS & ANALYSIS

TRENDING LEGAL ANALYSIS

Upcoming Legal Education Events

Wednesday, January 18, 2017
Thursday, January 19, 2017
Wednesday, January 25, 2017
Thursday, January 26, 2017
Friday, January 27, 2017
Wednesday, February 1, 2017
Thursday, February 9, 2017
Wednesday, February 15, 2017